Neoadjuvant treatment with cetuximab, 5-fluorouracil, folinic acid and oxaliplatin in unresectable retroperitoneal recurrent colon cancer

被引：8

作者：

Trojan, J. ^{[1
]}

Lubomierski, N. ^{[1
]}

Lehnert, T. ^{[2
]}

Engels, K. ^{[3
]}

Zeuzem, S. ^{[1
]}

Bechstein, W. O. ^{[4
]}

机构：

[1] Klinikum Johann Wolfgang Goethe Univ, Med Klin 1, D-60590 Frankfurt, Germany

[2] Klinikum Johann Wolfgang Goethe Univ, Inst Diagnost & Intervent Radiol, D-60590 Frankfurt, Germany

[3] Klinikum Johann Wolfgang Goethe Univ, Senckenberg Inst Pathol, D-60590 Frankfurt, Germany

[4] Klinikum Johann Wolfgang Goethe Univ, Klin Allgemein & Gefasschirurg, D-60590 Frankfurt, Germany

来源：

ZEITSCHRIFT FUR GASTROENTEROLOGIE | 2008年 / 46卷 / 08期

关键词：

colon cancer; locoregional recurrence; neoadjuvant treatment; molecular targeted therapy; surgery;

D O I：

10.1055/s-2007-963717

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Some patients with initially unresectable hepatic colorectal cancer metastases can be effectively treated with neoadjuvant chemotherapy to allow operative resection in curative intent. Here, we report on a patient with unresectable locoregional recurrence of colon cancer, which was down-staged using combination chemotherapy with infusional 5-fluorouracil, folinic acid, oxaliplatin and cetuximab. After 12 weeks of therapy a partial response was documented and 3 weeks later the tumor was completely resected without increased perioperative morbidity. Therefore, neoadjuvant treatment with molecular targeted agents in combination with chemotherapy can also be an option to enable selected patients with locoregional recurrence to undergo surgical resection in curative intent.

引用

页码：776 / 779

页数：4

共 13 条

[1]

ANDRE T, 2007, GASTR CANC S, pA334

[2]

ARNOLD D, 2007, J CLIN ONCOL S, V25, pA4042

[3]

Bokemeyer C, 2007, J CLIN ONCOL, V25

[4]

BORNER M, 2006, J CLIN ONCOL S, V24, pA3551

[5] Operative salvage for locoregional recurrent colon cancer after curative resection: An analysis of 100 cases [J].

Bowne, WB ;

Lee, B ;

Wong, WD ;

Ben-Porat, L ;

Shia, J ;

Cohen, AM ;

Enker, WE ;

Guillem, JG ;

Paty, PB ;

Weiser, MR .

DISEASES OF THE COLON & RECTUM, 2005, 48 (05) :897-909

[6] Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer [J].

Cunningham, D ;

Humblet, Y ;

Siena, S ;

Khayat, D ;

Bleiberg, H ;

Santoro, A ;

Bets, D ;

Mueser, M ;

Harstrick, A ;

Verslype, C ;

Chau, I ;

Van Cutsem, E .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (04) :337-345

[7] Lack of evidence for increased operative morbidity after hepatectomy with perioperative use of bevacizumab: A matched case-control study [J].

D'Angelica, Michael ;

Kornprat, Peter ;

Gonen, Mithat ;

Chung, Ki-Young ;

Jarnagin, William R. ;

DeMatteo, Ronald P. ;

Fong, Yuman ;

Kemeny, Nancy ;

Blumgart, Leslie H. ;

Saltz, Leonard B. .

ANNALS OF SURGICAL ONCOLOGY, 2007, 14 (02) :759-765

[8] Surgical resection after downsizing of colorectal liver metastasis in the era of bevacizumab [J].

Ellis, LM ;

Curley, SA ;

Grothey, A .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (22) :4853-4855

[9] Surgery for recurrent colon cancer: Strategies for identifying resectable recurrence and success rates after resection [J].

Goldberg, RM ;

Fleming, TR ;

Tangen, CM ;

Moertel, CG ;

Macdonald, JS ;

Haller, DG ;

Laurie, JA .

ANNALS OF INTERNAL MEDICINE, 1998, 129 (01) :27-+

[10]

GRUENBERGER B, 2007, J CLIN ONCOL S, V25, pA4060

← 1 2 →